First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

NCT02896231 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: PLB1001

Sponsor

Beijing Pearl Biotechnology Limited Liability Company